This post was originally published on this site Combining the immune checkpoint inhibitor Keytruda (pembrolizumab) with either a PARP inhibitor, chemotherapy, or hormone therapy led to promising signs of activity in metastatic castration-resistant prostate cancer (mCRPC) patients in a Phase 1b/2 trial, Merck — Keytruda’s developer — announced. The findings were presented at the 2019…
This post was originally published on this site Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a combination of Revlimid (lenalidomide) and Rituxan (rituximab), compared to Rituxan alone, a Phase 3 trial shows. The combination was also superior…
This post was originally published on this site Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase 2 trial shows. The combination also extended the time patients lived without signs of disease worsening compared with…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase 3 trial (NCT02755597). This means that all ongoing clinical trials assessing AbbVie‘s venetoclax in multiple myeloma can no…
This post was originally published on this site A combination of the immunotherapies Keytruda (pembrolizumab) and CRS-207 is safe, but has no evidence of clinical activity in adults with malignant pleural mesothelioma who failed prior lines of therapy, a Phase 2 study shows. Based on the findings and on additional data from CRS-207’s program, the therapy’s clinical…
This post was originally published on this site Screening a woman’s breast cancer for certain genetic and molecular patterns may be used to predict the risk of the cancer returning (relapsing) up to 20 years later, a study reports. Looking at the molecular data of breast tumors of nearly 2,000 women, researchers identified specific tumor…
This post was originally published on this site Xynomic Pharma is preparing two new Phase 2 trials in China to explore the activity of its investigational HDAC inhibitor, abexinostat, as third-line therapy for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The trials were approved by an independent ethics committee and will be conducted…
This post was originally published on this site Seres Therapeutics and AstraZeneca have established a research collaboration to unravel the mechanisms by which the microbiome – the natural, beneficial community of microbes living in the gut — might enhance the efficacy of cancer immunotherapies. “Our new collaboration with Seres Therapeutics represents an important opportunity to…
This post was originally published on this site While current clinical data support no difference in the survival outcomes of prostate cancer patients after robotic surgery or radiation therapy, men tend to prefer surgery after consulting with their urologists and radiation oncologists, according to a small Australian study. Researchers found that treatment choices were primarily…
This post was originally published on this site Proteomic analysis — the characterization of all proteins present in a cell at a given time — in liquid biopsies from the womb may facilitate the early diagnosis of women who are genetically predisposed to develop high-grade ovarian cancer (HGOC), a study says. The study, “Microvesicle Proteomic…
